A tumor marker is a biomarker found in blood, urine, or body tissues that can be elevated by the presence of one or more types of cancer. These markers may be used, along with other tests and procedures, to help detect and diagnose some types of cancer, predict, and monitor a person's response to certain treatments, and detect recurrence.
Saudi Arabia Tumor Marker Market Analysis, 2020 research report depicts a deep dive market analysis of statistics of Saudi Arabia Tumor Marker market which consists of regional and country-wise market size, forecast, CAGR market segmentation, market shares of diverse regions and countries, market share of various end-users, applications, product type, technologies, competitive benchmarking, etc.
According to MarkNtel Advisors’ research report “Saudi Arabia Tumor Marker Market Analysis, 2020”, the Saudi Arabia Tumor Marker market is anticipated to grow at a substantial CAGR during 2020-25. The growth of the market is attributed to significantly rising cancer cases in the country especially breast cancer in women and lung cancer men. According to WHO, the cancer cases are estimated to rise from 24,485 cases in 2018 to 54, 240 cases by 2040. Along with this, booming aging population, surging government investments on R&D activities, and the launch of various campaigns to increase awareness amongst people for treatment and early detection of the cancer is projected to place an optimistic impact on the growth of the market in the coming years.
Breast and Lung Cancer Grabbed the Largest Market Share
Breast cancer and Lung cancer captured the largest market share in Saudi Arabia Tumor Marker Market in 2019. The growth of the segment is attributed to burgeoning investment towards the advancements in medicine and technology to increase survival rates among patients, rising elderly population and obesity rate along with the launch of a various breast awareness campaign for public awareness and escalating vitamin D deficiency. Lung cancer is the 5th most common cancer among Saudi males due to the growing smoking amongst men. However, Breast cancer is the most frequently diagnosed cancer site and also the leading cause of death among women. Total number of breast and lung cancer cases in 2018 was 3,621 and 923 respectively which are estimated to reach around 6,886 and 3,066 by 2040 as revealed by MarkNtel Advisors’ research report “Saudi Arabia Tumor Marker Market Analysis, 2020”.
According to MarkNtel Advisors’, the key players with a considerable market share in the Saudi Arabia Tumor Marker market include Fujirebio, Randox, Bio-Rad, Cepheid, Roche, MP Biomedicals, DiaSorin, Leica Biosystems, Biomerieux, etc.
Key Questions Answered in the Market Research Report
Market Outlook, Segmentation and Statistics
Frequently Asked Questions
Q. What is the historical year, base year and forecast year considered in the research report on Saudi Arabia Tumor Marker Market?
A. The historical data has been provided since 2015, while the base year is 2019 and the data is forecast up-to 2025.
Q. Who are the key competitors or players operating in the Saudi Arabia Tumor Marker Market?
A Fujirebio, Randox, Bio-Rad, Cepheid, Roche, MP Biomedicals, DiaSorin, Leica Biosystems, Biomerieux, etc. are few of the leading players in the Saudi Arabia Tumor Marker Market.
Q. Which cancer type segment would emerge as an opportunity area for players in Saudi Arabia Tumor Marker Market?
A. The breast cancer segment is expected to attain the highest CAGR during the forecast period and maintain its significant market share.
Q. Which application segment would emerge as an opportunity area for players in Saudi Arabia Tumor Marker Market?
A. The diagnosis segment is the leading application segment in the Saudi Arabia Tumor Marker market.
